Skip to main content

Atossa Therapeutics, Inc.

ATOS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001488039

No open-market purchases or sales by Atossa Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $2.60M in total; no superinvestor holds it.

Q1 2026 vs. Q4 2025

How the institutions holding Atossa Therapeutics, Inc. changed between Q4 2025 and Q1 2026.

All holders in Q1 2026All holders in Q4 2025

13F holders of ATOS: Q4 2025 compared with Q1 2026
MeasureQ4 2025Of which not filed for Q1 2026Q1 2026Change
Holders67233−32
SharesConverted for a 1-for-15 split1.47M411.1K1.24M+185.6K (+17.6%)
Value$13.0M$3.64M$6.52M−$2.81M (−30.1%)

2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (7)

Institutions that held Atossa Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to ATOS in Q1 2026
InstitutionSharesValue% of portfolio
Vanguard Capital Management LLC349,096$1.84M0.00%
Vanguard Fiduciary Trust Co52,235$274.8K0.00%
Vanguard Global Advisers, LLC3,089$16.2K0.00%
Avion Wealth318$1.00K0.00%
North Star Investment Management Corp.80$4210.00%
Napier Financial, LLC6$320.00%
Bogart Wealth, LLC5$260.00%

Sold out (39)

Institutions that held Atossa Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.

Not filed for Q1 2026 yet (2)

Institutions that held Atossa Therapeutics, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ATOS in Q4 2025 that haven't filed for Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Vanguard Group Inc6,147,838$3.63M
Greenberg Financial Group18,216$10.7K